INmune Bio
INMB
37 hedge funds and large institutions have $14.5M invested in INmune Bio in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
12% more funds holding
Funds holding: 33 → 37 (+4)
0.67% more ownership
Funds ownership: 11.18% → 11.85% (+0.67%)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
20% less capital invested
Capital invested by funds: $18.2M → $14.5M (-$3.73M)
38% less call options, than puts
Call options by funds: $258K | Put options by funds: $416K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FA
Fermata Advisors
Sonoma,
California
|
+$470K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$317K |
| 3 |
Bank of New York Mellon
New York
|
+$273K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$269K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$194K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$256K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$212K |
| 3 |
Renaissance Technologies
New York
|
-$182K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$92.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$86.3K |
INMB Hedge Fund Activity: Q3 2023 in Review
37 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q3 2023, worth a combined $14.5M — down 20% from $18.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new INMB positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Fermata Advisors, opening a new position worth an estimated $470K. The largest seller was Millennium Management, exiting entirely with an estimated $256K sold.
- 37 institutional investors held INmune Bio (INMB) as of Q3 2023, up from 33 in Q2 2023.
- Funds reported $14.5M of INmune Bio stock for Q3 2023, down 20% quarter-over-quarter.
- 7 funds opened new INmune Bio positions in Q3 2023 and 3 closed out, a net change of +4 holders.
- The largest INmune Bio buyer in Q3 2023 was Fermata Advisors, an estimated $470K added.
- The largest INmune Bio seller in Q3 2023 was Millennium Management, an estimated $256K sold.
Based on aggregated 13F filings for Q3 2023.